Table 1 Characteristics of patient samples in the pools
From: Expression patterns of microRNAs associated with CML phases and their disease related targets
Pools | Patient number (gender) | IM therapy (months) | WBC count (*109/L PB) | Thrombocyte count (*109/L PB) | Blast count (% in PB) | BCR-ABL (%) | Ph+ cells (%) | Pretreatment | BCR-ABL mutations |
|---|---|---|---|---|---|---|---|---|---|
Dg | 1 (F) | 0 | 71.4 | 749 | 0 | 60 | 100 | HU | NA |
2 (F) | 0 | 66.5 | 824 | 3 | 131 | 100 | HU | NA | |
3 (M) | 0 | 22.3 | 509 | 1 | 144 | 100 | HU | NA | |
4 (M) | 0 | 15.5 | 636 | 0 | 312 | 100 | HU | NA | |
5 (M) | 0 | 198.5 | 550 | 1 | 139 | 100 | HU, IFN | NA | |
MMR | 6 (M) | 14.8 | 5.7 | 244 | 0 | 0.001 | 0 | HU | NA |
7 (F) | 7.4 | 5.3 | 153 | 0 | 0.01 | 0 | HU | NA | |
8 (M) | 9.2 | 6.1 | 181 | 0 | 0.001 | 0 | HU | NA | |
9 (M) | 19.6 | 4.2 | 309 | 0 | 0.04 | 0 | HU | NA | |
10 (M) | 13.1 | 4.8 | 230 | 0 | 0.02 | 0 | HU | NA | |
TF | 11 (F) | 17.6 | 4.8 | 224 | 0 | 37 | 90 | IFN | M351T |
12 (M) | 14.3 | 4.2 | 142 | 0 | 15 | 100 | HU | WT | |
13 (F) | 15.1 | 5.4 | 252 | 0 | 37 | 30 | HU | WT | |
14 (F) | 13.5 | 2.4 | 100 | 0 | 23 | 60 | HU, IFN | WT | |
15 (M) | 13.1 | 4.5 | 171 | 0 | 38 | 100 | HU | WT | |
Hr | 16 (M) | 13.6 | 28.1 | 448 | 0 | 80 | 100 | HU | M351T, F317L |
17 (F) | 16.6 | 14.0 | 440 | 0 | 212 | 100 | HU, IFN | F311I | |
18 (M) | 16.5 | 17.3 | 444 | 0 | 68 | 100 | IFN, HU | M244V | |
19 (F) | 25.3 | 16.2 | 550 | 0 | 66 | 100 | IFN | M351T | |
20 (M) | 22.4 | 26.1 | 245 | 0 | 164 | 100 | IFN, HU | F317L | |
BC | 21 (F) | 55.4 | 65.6 | 147 | 62 | 1883 | 100 | NA | M244V |
22 (M) | 6.7 | 17.8 | 494 | 51 | 2188 | 100 | NA | WT | |
23 (M) | 33.0 | 55.7 | 14 | 79 | 2500 | 100 | NA | WT | |
24 (M) | 36.7 | 8.0 | 21 | 76 | 1000 | 100 | NA | M351T, D276G |